NASDAQ:PHAT Phathom Pharmaceuticals (PHAT) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free PHAT Stock Alerts $9.20 +0.14 (+1.55%) (As of 11:10 AM ET) Add Compare Share Share Today's Range$9.04▼$9.3250-Day Range$6.61▼$12.0552-Week Range$6.07▼$17.02Volume94,446 shsAverage Volume830,913 shsMarket Capitalization$538.38 millionP/E RatioN/ADividend YieldN/APrice Target$21.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Phathom Pharmaceuticals alerts: Email Address Phathom Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside129.9% Upside$21.33 Price TargetShort InterestBearish39.95% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.11Based on 8 Articles This WeekInsider TradingSelling Shares$30.19 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.22) to ($3.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.80 out of 5 starsMedical Sector600th out of 909 stocksPharmaceutical Preparations Industry270th out of 423 stocks 3.4 Analyst's Opinion Consensus RatingPhathom Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePhathom Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted39.95% of the float of Phathom Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPhathom Pharmaceuticals has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.Change versus previous monthShort interest in Phathom Pharmaceuticals has recently increased by 2.01%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPhathom Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhathom Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PHAT. Previous Next 1.7 News and Social Media Coverage News SentimentPhathom Pharmaceuticals has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Phathom Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for PHAT on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Phathom Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Phathom Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $30,191,635.00 in company stock.Percentage Held by Insiders24.10% of the stock of Phathom Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.01% of the stock of Phathom Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Phathom Pharmaceuticals are expected to grow in the coming year, from ($4.22) to ($3.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Phathom Pharmaceuticals is -2.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phathom Pharmaceuticals is -2.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Phathom Pharmaceuticals Stock (NASDAQ:PHAT)Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Read More PHAT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHAT Stock News HeadlinesApril 11, 2024 | insidertrades.comMolly Henderson Sells 3,435 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) StockMarch 27, 2024 | insidertrades.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Terrie Curran Sells 16,851 SharesApril 24, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.April 23, 2024 | markets.businessinsider.comNeedham Keeps Their Hold Rating on Lexicon Pharmaceuticals (LXRX)April 21, 2024 | americanbankingnews.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 3.7%April 21, 2024 | americanbankingnews.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Rating Reaffirmed by Needham & Company LLCApril 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Alimera (ALIM)April 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Phathom Pharmaceuticals Amid Strong Uptake of V oqueznaApril 24, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.April 19, 2024 | finance.yahoo.com12 Most Shorted Stocks in 2024April 14, 2024 | americanbankingnews.comPhathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 3%April 12, 2024 | investing.comPhathom Pharmaceuticals CFO sells over $38k in company stockApril 10, 2024 | markets.businessinsider.comBuy Rating Justified by Rhythm Pharmaceuticals’ Strong Market Entry and Promising PipelineApril 9, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD)April 7, 2024 | msn.comPhathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analystApril 6, 2024 | markets.businessinsider.comOptimistic Outlook for Phathom Pharmaceuticals’ Voquezna Despite Prescription Data FluctuationsApril 5, 2024 | finance.yahoo.comARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist InvestorsApril 3, 2024 | finance.yahoo.comPhathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceApril 3, 2024 | globenewswire.comPhathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceApril 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Achieve Life Sciences (ACHV) and Phathom Pharmaceuticals (PHAT)March 28, 2024 | stockhouse.comPhathom Pharmaceuticals Launches Direct-to-Consumer Campaign, "VOQUEZNA Can Kick Some Acid"March 28, 2024 | investing.comPhathom Pharmaceuticals CEO sells shares worth over $153,000March 26, 2024 | finance.yahoo.comPhathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”March 25, 2024 | finance.yahoo.comSIGA Names Larry Miller General CounselMarch 23, 2024 | markets.businessinsider.comPositive Prescription Trends and Resilience Prompt Buy Rating for Phathom PharmaceuticalsMarch 18, 2024 | seekingalpha.comPhathom: Undervalued Biotech With Possible GERD Treatment Label ExpansionMarch 16, 2024 | finance.yahoo.comPHAT Apr 2024 10.000 callSee More Headlines Receive PHAT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Phathom Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/24/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PHAT CUSIPN/A CIK1783183 Webwww.phathompharma.com Phone877-742-8466FaxN/AEmployees452Year FoundedN/APrice Target and Rating Average Stock Price Target$21.33 High Stock Price Target$28.00 Low Stock Price Target$10.00 Potential Upside/Downside+131.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-201,590,000.00 Net MarginsN/A Pretax Margin-29,558.95% Return on EquityN/A Return on Assets-63.40% Debt Debt-to-Equity RatioN/A Current Ratio10.25 Quick Ratio10.22 Sales & Book Value Annual Sales$680,000.00 Price / Sales791.74 Cash FlowN/A Price / Cash FlowN/A Book Value($1.27) per share Price / Book-7.24Miscellaneous Outstanding Shares58,520,000Free Float44,420,000Market Cap$538.38 million OptionableOptionable Beta0.63 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMs. Terrie J. Curran (Age 55)President, CEO & Director Comp: $1.11MMr. David A. Socks (Age 49)Co-Founder & Director Comp: $58.78kDr. Azmi Nabulsi M.D. (Age 65)M.P.H., Co-Founder & COO Comp: $815.21kMs. Molly Henderson CPA (Age 53)MBA, Chief Financial & Business Officer Comp: $671.27kDr. Aditya Kohli Ph.D. (Age 35)Co-Founder Comp: $319.65kMr. Lawrence R. Miller Esq.J.D., General Counsel & SecretaryMr. Tom HarrisChief Development Sciences OfficerDr. Eckhard Leifke M.D.Ph.D., Chief Medical OfficerMr. Martin J. GilliganChief Commercial OfficerMore ExecutivesKey CompetitorsAstria TherapeuticsNASDAQ:ATXSArriVent BioPharmaNASDAQ:AVBPAltimmuneNASDAQ:ALTStoke TherapeuticsNASDAQ:STOKKorro BioNASDAQ:KRROView All CompetitorsInsiders & InstitutionsMedicxi Ventures Management Jersey LtdBought 3,703,703 shares on 4/15/2024Ownership: 12.764%Molly HendersonSold 3,435 sharesTotal: $38,128.50 ($11.10/share)Terrie CurranSold 16,851 sharesTotal: $153,512.61 ($9.11/share)Wellington Management Group LLPBought 54,581 shares on 3/5/2024Ownership: 0.270%Octagon Capital Advisors LPBought 50,000 shares on 2/15/2024Ownership: 0.087%View All Insider TransactionsView All Institutional Transactions PHAT Stock Analysis - Frequently Asked Questions Should I buy or sell Phathom Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Phathom Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PHAT shares. View PHAT analyst ratings or view top-rated stocks. What is Phathom Pharmaceuticals' stock price target for 2024? 4 Wall Street analysts have issued 1 year price objectives for Phathom Pharmaceuticals' stock. Their PHAT share price targets range from $10.00 to $28.00. On average, they predict the company's share price to reach $21.33 in the next twelve months. This suggests a possible upside of 129.9% from the stock's current price. View analysts price targets for PHAT or view top-rated stocks among Wall Street analysts. How have PHAT shares performed in 2024? Phathom Pharmaceuticals' stock was trading at $9.13 at the beginning of the year. Since then, PHAT stock has increased by 1.6% and is now trading at $9.28. View the best growth stocks for 2024 here. When is Phathom Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our PHAT earnings forecast. How were Phathom Pharmaceuticals' earnings last quarter? Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) issued its earnings results on Thursday, March, 7th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.12. The company earned $0.68 million during the quarter, compared to analyst estimates of $0.93 million. During the same quarter last year, the firm posted ($1.33) EPS. What ETFs hold Phathom Pharmaceuticals' stock? ETFs with the largest weight of Phathom Pharmaceuticals (NASDAQ:PHAT) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of Phathom Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Phathom Pharmaceuticals investors own include Clovis Oncology (CLVS), AbbVie (ABBV), Algonquin Power & Utilities (AQN), BCE (BCE), Cinemark (CNK), CenterPoint Energy (CNP), Canadian Natural Resources (CNQ), Brinker International (EAT) and Consolidated Edison (ED). When did Phathom Pharmaceuticals IPO? Phathom Pharmaceuticals (PHAT) raised $150 million in an initial public offering on Friday, October 25th 2019. The company issued 7,900,000 shares at $18.00-$20.00 per share. Goldman Sachs, Jefferies and Evercore ISI acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Phathom Pharmaceuticals' major shareholders? Phathom Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Medicxi Ventures Management Jersey Ltd (12.76%). Insiders that own company stock include Asit Parikh, Azmi Nabulsi, David A Socks, Molly Henderson, Nathan Olmstead, Peter Bauer, Pharmaceutical Co Ltd Takeda and Terrie Curran. View institutional ownership trends. How do I buy shares of Phathom Pharmaceuticals? Shares of PHAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PHAT) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchTiny Biotech Stock Wins $75 Billion PatentBehind the MarketsI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
